MedWatch

Novo Nordisk plans to invest DKK 500m in expanding tablet production facilities

Wishing to generate further capacity for the future production of diabetes tablet Rybelsus, Novo Nordisk plans to invest DKK 500m in an expansion of the company's production facilities in Denmark.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Danish pharmaceutical company Novo Nordisk plans to invest DKK 500m in expanding the company's production facilities near Copenhagen in Denmark, informs the company in a press release Thursday morning.

According to the company, this is to ensure the company's production capacity for the diabetes drug Rybelsus, which is based on the molecule semaglutide.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs